Drug treatments of T2DM aim to decrease hepatic glucose production, enhance insulin action, and boost insulin secretion from β-pancreatic cells, or block α-glycosidase enzyme (carbohydrate digestive enzymes).3–6. This evidence concerns the gene INS and type 2 diabetes mellitus.